Chelsea Therapeutics International reports positive study results
Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) reported positive results from its human bioequivalence study of its lead product candidate in the pharmaceutical company to be used in a Phase II evaluation in the treatment of rheumatoid arthritis.
Specifically, the company quantified the improvements in relative bioavailability demonstrated by disodium salt formulation of CH-1504 and identified doses to be used in a Phase II evaluation in the treatment of rheumatoid arthritis
Shares of Chelsea jumped 12.93%, or $0.79 to $6.90 in pre-market trading.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
